Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 3
2006 2
2008 3
2009 4
2010 2
2011 3
2012 1
2013 1
2020 1
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

19 results
Results by year
Filters applied: . Clear all
Page 1
Clinical pharmacokinetics of trospium chloride.
Doroshyenko O, Jetter A, Odenthal KP, Fuhr U. Doroshyenko O, et al. Clin Pharmacokinet. 2005;44(7):701-20. doi: 10.2165/00003088-200544070-00003. Clin Pharmacokinet. 2005. PMID: 15966754 Review.
Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric?
Tomalik-Scharte D, Lütjohann D, Doroshyenko O, Frank D, Jetter A, Fuhr U. Tomalik-Scharte D, et al. Among authors: doroshyenko o. Clin Pharmacol Ther. 2009 Aug;86(2):147-53. doi: 10.1038/clpt.2009.72. Epub 2009 May 20. Clin Pharmacol Ther. 2009. PMID: 19458613
Absorption, pharmacokinetics, and safety of triclosan after dermal administration.
Queckenberg C, Meins J, Wachall B, Doroshyenko O, Tomalik-Scharte D, Bastian B, Abdel-Tawab M, Fuhr U. Queckenberg C, et al. Among authors: doroshyenko o. Antimicrob Agents Chemother. 2010 Jan;54(1):570-2. doi: 10.1128/AAC.00615-09. Epub 2009 Oct 12. Antimicrob Agents Chemother. 2010. PMID: 19822703 Free PMC article.
No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam.
Tomalik-Scharte D, Doroshyenko O, Kirchheiner J, Jetter A, Lazar A, Klaassen T, Frank D, Wyen C, Fätkenheuer G, Fuhr U. Tomalik-Scharte D, et al. Among authors: doroshyenko o. Eur J Clin Pharmacol. 2008 Oct;64(10):1033-5. doi: 10.1007/s00228-008-0503-9. Epub 2008 Jun 28. Eur J Clin Pharmacol. 2008. PMID: 18587567 Free article. No abstract available.
Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients.
Arshad U, Ploylearmsaeng SA, Karlsson MO, Doroshyenko O, Langer D, Schömig E, Kunze S, Güner SA, Skripnichenko R, Ullah S, Jaehde U, Fuhr U, Jetter A, Taubert M. Arshad U, et al. Among authors: doroshyenko o. Cancer Chemother Pharmacol. 2020 Apr;85(4):711-722. doi: 10.1007/s00280-019-04028-5. Epub 2020 Mar 9. Cancer Chemother Pharmacol. 2020. PMID: 32152679 Free PMC article.
Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.
Kirchheiner J, Thomas S, Bauer S, Tomalik-Scharte D, Hering U, Doroshyenko O, Jetter A, Stehle S, Tsahuridu M, Meineke I, Brockmöller J, Fuhr U. Kirchheiner J, et al. Among authors: doroshyenko o. Clin Pharmacol Ther. 2006 Dec;80(6):657-67. doi: 10.1016/j.clpt.2006.09.008. Clin Pharmacol Ther. 2006. PMID: 17178266 Clinical Trial.
19 results